Investment in African healthcare needs African evidence.
Commercial launch risk. Fragmented health information. Local manufacturing ambition. The evidence question is becoming an investment question.
01 / EXTERNAL CONTEXT~1 in 3
US drug launches fell short of launch-year forecasts
Commercial uncertainty is not only a clinical problem. Among 91 underperformers reviewed, 57% cited market access and 41% inadequate understanding of market needs.
Local health-product manufacturing ambition by 2040
The African Union has set an ambition to meet at least 60% of Africa’s health-product needs through local manufacturing by 2040. A goal, not current output.
WHO identifies fragmentation, weak interoperability and governance as barriers to using health data across the African Region. The opportunity is to make appropriate local evidence useful for a defined decision.
At the 3 October 2026 Alamein Africa Forum, President John Dramani Mahama stated that Africa imports over 70% of its pharmaceuticals and nearly 99% of its vaccines. These are attributed keynote figures, not I&E measurements.
Sources & context · Last reviewed: October 2026. All statistics describe external research, supply or policy context, not I&E datasets, activities or access rights.
THE NEXT DECISION STARTS WITH A QUESTION
What do you need to know before you act?
Bring us the healthcare decision you are facing. Let’s determine what evidence can answer it.
